On Invalid Date, Biogen (NASDAQ: BIIB) reported Q1 2023 earnings per share (EPS) of $2.69, up 30.58% year over year. Total Biogen earnings for the quarter were $387.90 million. In the same quarter last year, Biogen's earnings per share (EPS) was $2.06.
As of Q2 2023, Biogen's earnings has grown 121.04% year over year. This is 125.36 percentage points higher than the US Drug Manufacturers - General industry earnings growth rate of -4.32%. Biogen's earnings in the past year totalled $3.13 billion.
On Invalid Date, Biogen (NASDAQ: BIIB) reported Q1 2023 revenue of $2.46 billion up 2.72% year over year. In the same quarter last year, Biogen's revenue was $2.53 billion.
What was BIIB's revenue growth in the past year?
As of Q2 2023, Biogen's revenue has grown -6.61% year over year. This is 7.25 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 0.65%. Biogen's revenue in the past year totalled $10.10 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.